| Acquired by | Silence Therapeutics |
| Date | 12/09 |
| Website | intradigm.com |
| Category | BioTech |
| Phone | (650) 855 9696 |
| Employees | |
| Founded | 2000 |
| Description | Healthcare Biotechnology |
| TOTAL | $37.4M |
| FUNDING TOTAL | $37.4M |
| Series A, 11/06 Alta Partners Frazier Healthcare Ventures Emerging Technology Partners Novartis Venture Funds MediBic Alliance | $16M |
| Series B, 1/09 MP Healthcare Venture Management Frazier Healthcare Ventures Astellas Venture Management MediBic Alliance Alta Partners Lilly Ventures Novartis Venture Fund Roche Venture Fund | $21.4M |
Private biotechnology company that develops systematic RNA interference (RNAi) therapeutics for the treatment of serious diseases with an initial focus on oncology. The company’s expertise in drug development and delivery serves as the foundation of Intradigm’s RNAi platform. In particular, the company’s proprietary RNAi Nanoplex delivery technology is unique in its ability to enable the targeted delivery of RNAi therapeutics to specific tissues through systemic administration of the drug product.
